A detailed history of Royal Bank Of Canada transactions in Celcuity Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 10,507 shares of CELC stock, worth $134,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,507
Previous 9,947 5.63%
Holding current value
$134,279
Previous $162,000 3.7%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.98 - $19.15 $7,828 - $10,724
560 Added 5.63%
10,507 $156,000
Q2 2024

Aug 14, 2024

BUY
$14.1 - $20.78 $25,112 - $37,009
1,781 Added 21.81%
9,947 $162,000
Q1 2024

Nov 05, 2024

SELL
$13.74 - $21.6 $24,470 - $38,469
-1,781 Reduced 17.9%
8,166 $176,000
Q1 2024

May 15, 2024

SELL
$13.74 - $21.6 $147,608 - $232,048
-10,743 Reduced 56.81%
8,166 $176,000
Q4 2023

Feb 14, 2024

BUY
$8.7 - $15.02 $17,574 - $30,340
2,020 Added 11.96%
18,909 $275,000
Q3 2023

Nov 14, 2023

BUY
$8.96 - $10.75 $64,646 - $77,561
7,215 Added 74.58%
16,889 $154,000
Q2 2023

Aug 14, 2023

BUY
$9.39 - $12.18 $22,761 - $29,524
2,424 Added 33.43%
9,674 $106,000
Q4 2022

Feb 14, 2023

SELL
$7.55 - $14.01 $15 - $28
-2 Reduced 0.03%
7,250 $101,000
Q3 2022

Nov 14, 2022

BUY
$8.0 - $10.64 $16 - $21
2 Added 0.03%
7,252 $73,000
Q2 2022

Aug 15, 2022

BUY
$5.35 - $10.11 $2,172 - $4,104
406 Added 5.93%
7,250 $66,000
Q1 2022

May 16, 2022

SELL
$7.93 - $13.33 $13,488 - $22,674
-1,701 Reduced 19.91%
6,844 $64,000
Q4 2021

Feb 14, 2022

BUY
$11.96 - $19.35 $8,300 - $13,428
694 Added 8.84%
8,545 $113,000
Q3 2021

Nov 15, 2021

BUY
$17.35 - $24.87 $26,979 - $38,672
1,555 Added 24.7%
7,851 $142,000
Q2 2021

Aug 16, 2021

BUY
$14.25 - $30.93 $89,718 - $194,735
6,296 New
6,296 $151,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $191M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.